Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

Transient scaffolding using bioresorbable drug-eluting polymeric platforms aims to improve late clinical outcomes through restoration of vasomotion, adaptive shear stress, late plaque regression and expansive remodelling. However, long-term data are scarce. Several studies have reported the midterm comparison of the Absorb™ bioresorbable scaffold (Abbott Vascular, Santa Clara, CA, USA) with its metallic stent counterpart, XIENCE® (Abbott Vascular). Preclinical evaluation has shown that scaffold degradation is complete by 36 months3. The aim of this report is to present the first four-year comparative evaluation after the expected full resorption of the scaffold device.

• View at Publisher
• View at Scopus